Mode
Text Size
Log in / Sign up
Phase 3 N=52 Treatment

Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening

Attention Deficit-Hyperactivity

Enrolled (actual)
52
Serious AEs
0.0%
Results posted
Jun 2023
Primary outcome: Primary: Adult ADHD Investigator Symptom Rating Scale (AISRS) Score at End of Placebo Lead-In — 37.2 score on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
MYDAYIS (Drug); Placebo (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
NYU Langone Health
Primary completion
May 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Adult ADHD Investigator Symptom Rating Scale (AISRS) Score at End of Placebo Lead-In
37.2
PRIMARY
Adult ADHD Investigator Symptom Rating Scale (AISRS) Score at End of Mydayis Treatment
18.5
SECONDARY
AISRS: Overall Inattentive (IA) Symptom Subscale Score at End of Placebo Lead-In
19.9
SECONDARY
AISRS: Overall Inattentive (IA) Symptom Subscale Score at End of Mydayis Treatment
9.6
SECONDARY
AISRS: Hyperactive-Impulsive (HI) Symptom Subscale Score at End of Placebo Lead-In
17.3
SECONDARY
AISRS: Hyperactive-Impulsive (HI) Symptom Subscale Score at End of Mydayis Treatment
8.8
SECONDARY
Clinical Global Impression-Severity (CGI-S) Scale Score at End of Placebo Lead-In
4.6
SECONDARY
Clinical Global Impression-Severity (CGI-S) Scale Score at End of Mydayis Treatment
3.1
SECONDARY
14-Hour Post-Dose Time-Sensitive Adult ADHD Symptom Scale (TASS) Score at End of Placebo Lead-In
24.6
SECONDARY
14-Hour Post-Dose Time-Sensitive Adult ADHD Symptom Scale (TASS) Score at End of Mydayis Treatment
16.8
SECONDARY
14-hour Post-Dose TASS: Inattentive (IA) Symptom Subscale Score at End of Placebo Lead-In
15.4
SECONDARY
14-hour Post-Dose TASS: Inattentive (IA) Symptom Subscale Score at End of Mydayis Treatment
9.8
SECONDARY
14-hour Post-Dose TASS: Hyperactive-Impulsive (HI) Symptom Subscale Score at End of Placebo Lead-In
9.2
SECONDARY
14-hour Post-Dose TASS: Hyperactive-Impulsive (HI) Symptom Subscale Score at End of Mydayis Treatment
6.9
SECONDARY
Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score at Week 3
68.6
SECONDARY
Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score at Week 7
58.6
SECONDARY
WebNeuro Neurocognitive Assessment - Working Memory Capacity - Recall Span Score at Baseline
5.8
SECONDARY
WebNeuro Neurocognitive Assessment - Working Memory Capacity - Recall Span Score at Week 7
6.4
SECONDARY
WebNeuro Neurocognitive Assessment - Working Memory Capacity - Working Memory Accuracy at Baseline
6.9
SECONDARY
WebNeuro Neurocognitive Assessment - Working Memory Capacity - Working Memory Accuracy at Week 7
7.7
SECONDARY
WebNeuro Neurocognitive Assessment - Attention and Concentration - Reaction Time at Baseline
567.0
SECONDARY
WebNeuro Neurocognitive Assessment - Attention and Concentration - Reaction Time at Week 7
566.3
SECONDARY
WebNeuro Neurocognitive Assessment - Attention and Concentration - False Alarms at Baseline
1.3
SECONDARY
WebNeuro Neurocognitive Assessment - Attention and Concentration - False Alarms at Week 7
1.0
SECONDARY
WebNeuro Neurocognitive Assessment - Attention and Concentration - False Misses at Baseline
0.7
SECONDARY
WebNeuro Neurocognitive Assessment - Attention and Concentration - False Misses at Week 7
0.7
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Completion Time at Baseline
56771.9
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Completion Time at Week 7
47752.6
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Average Connection Time at Baseline
2228.0
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Average Connection Time at Week 7
1863.1
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Errors at Baseline
0.8
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Errors at Week 7
0.7
SECONDARY
WebNeuro Neurocognitive Assessment - Response Speed - Number of Taps at Baseline
189.6
SECONDARY
WebNeuro Neurocognitive Assessment - Response Speed - Number of Taps at Week 7
189.9
SECONDARY
WebNeuro Neurocognitive Assessment - Response Speed - Tapping Variability at Baseline
24.4
SECONDARY
WebNeuro Neurocognitive Assessment - Response Speed - Tapping Variability at Week 7
30.4
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Reaction Time at Baseline
379.2
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Reaction Time at Week 7
378.2
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Score (Words) at Baseline
15.4
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Score (Words) at Week 7
16.0
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Errors (Words) at Baseline
0.2
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Errors (Words) at Week 7
0.4
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Reaction Time (Words) at Baseline
1434.5
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Reaction Time (Words) at Week 7
1248.4
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Score (Colors) at Baseline
12.8
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Score (Colors) at Week 7
15.7
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Errors (Colors) at Baseline
0.3
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Errors (Colors) at Week 7
2.1
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Reaction Time (Colors) at Baseline
1526.8
SECONDARY
WebNeuro Neurocognitive Assessment - Information Processing Efficiency - Reaction Time (Colors) at Week 7
1176.2
SECONDARY
WebNeuro Neurocognitive Assessment - Executive Function - Trials Completed at Baseline
9.5
SECONDARY
WebNeuro Neurocognitive Assessment - Executive Function - Trials Completed at Week 7
8.1
SECONDARY
WebNeuro Neurocognitive Assessment - Executive Function - Completion Time at Baseline
234774.9
SECONDARY
WebNeuro Neurocognitive Assessment - Executive Function - Completion Time at Week 7
174054.1
SECONDARY
WebNeuro Neurocognitive Assessment - Executive Function - Path Learning Time at Baseline
204859.7
SECONDARY
WebNeuro Neurocognitive Assessment - Executive Function - Path Learning Time at Week 7
148589.5
SECONDARY
WebNeuro Neurocognitive Assessment - Executive Function - Total Errors at Baseline
37.1
SECONDARY
WebNeuro Neurocognitive Assessment - Executive Function - Total Errors at Week 7
26.3
SECONDARY
WebNeuro Neurocognitive Assessment - Executive Function - Number of Overruns at Baseline
14.8
SECONDARY
WebNeuro Neurocognitive Assessment - Executive Function - Number of Overruns at Week 7
12.8
SECONDARY
WebNeuro Neurocognitive Assessment - Impulsivity - Reaction Time at Baseline
308.2
SECONDARY
WebNeuro Neurocognitive Assessment - Impulsivity - Reaction Time at Week 7
307.8
SECONDARY
WebNeuro Neurocognitive Assessment - Impulsivity - False Alarms at Baseline
6.1
SECONDARY
WebNeuro Neurocognitive Assessment - Impulsivity - False Alarms at Week 7
5.2
SECONDARY
WebNeuro Neurocognitive Assessment - Impulsivity - False Misses at Baseline
1.9
SECONDARY
WebNeuro Neurocognitive Assessment - Impulsivity - False Misses at Week 7
0.3

Summary

Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder characterized by problems with sustaining attention, organization, planning, procrastination, daydreaming, restlessness, impulsivity and hyperactivity.This is an outpatient study for subjects between the ages of 18-60, who have an Attention deficit hyperactivity disorder (ADHD) diagnosis meeting all inclusion criteria and not meeting any of the exclusion criteria.

Eligibility Criteria

Inclusion Criteria

  • Male or female between the ages of 18-60 of all races and ethnicity.
  • Meets DSM V-TR criteria for a primary diagnosis of ADHD (including predominantly inattentive presentation, or combined presentation) as diagnosed via the Adult ADHD Clinician Diagnostic Scale version 1.2 (ACDS v1.2)

Exclusion Criteria

  • Meets DSM V-TR criteria for a primary diagnosis of hyperactive-impulsive type ADHD as diagnosed via the ACDS v1.2.
  • Any other current psychiatric disorder, determined via the M.I.N.I, which requires pharmacotherapy treatment.
  • Current suicidal ideation or history of suicide attempts, based on the Columbia- Suicide Severity Rating Scale(C-SSRS)
  • Lifetime history of bipolar disorder or any psychotic disorder as per the M.I.N.I
  • Pregnant, breastfeeding or women planning to become pregnant.
  • Positive urine drug toxicology are excluded.
  • Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the subject safety.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03945175). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search